Search
Search Results
##search.searchResults.foundPlural##
-
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
3257PDF: 1675HTML: 369 -
-
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3803PDF: 1349HTML: 2172Fig.1: 244Fig. 2: 238 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2829PDF: 878HTML: 15030Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 349 -
THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone
2591PDF: 1653HTML: 712 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2093PDF: 1683HTML: 807 -
GLUCOSE HOMEOSTASIS AND ΑSSESSMENT OF Β-CELL FUNCTION BY 3-HOUR ORAL GLUCOSE TOLERANCE (OGTT) IN PATIENTS WITH Β-THALASSEMIA MAJOR WITH SERUM FERRITIN BELOW 1,000 NG/DL: RESULTS FROM A SINGLE ICET-A CENTRE OGTT in thalassemia and iron overload
4069PDF: 1192HTML: 472 -
PREVENTION OF ? THALASSEMIA IN NORTHERN ISRAEL - A COST-BENEFIT ANALYSIS.
3246PDF: 1360HTML: 11862 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
3003PDF: 1016HTML: 7501 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
832PDF: 306Html: 45 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
5681PDF: 1083HTML: 482TABLE: 219FIGURES: 294 -
ASSOCIATION OF VDBP RS4701 VARIANT, BUT NOT VDR/RXR-? OVER-EXPRESSION WITH BONE MINERAL DENSITY IN PEDIATRIC ?-THALASSEMIA PATIENTS Vitamin D metabolic axis and BMD in ?-thalassemia
1376PDF: 780HTML: 290 -
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2377PDF: 1217HTML: 2617Study of serum haptoglobin level in thalassemia: 398Figures: 221 -
A MULTICENTER ICET-A STUDY ON AGE AT MENARCHE AND MENSTRUAL CYCLES IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA (TDT) WHO STARTED EARLY CHELATION THERAPY WITH DIFFERENT CHELATING AGENTS. Age at menarche and menstrual cycles in patients with transfusion-dependent thalassemia.
876PDF: 590HTML: 186 -
VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF
1399PDF: 911HTML: 1135Figure 1 the correlation between frequency of blood transfusion and serum vascular endothelial growth factor (VEGF).: 218 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
611PDF: 285HTML: 171 -
Does splenectomy influence the development of Hypothyroidism in Transfusion Dependent Thalassemia Patients? A retrospective study. Splenectomy in Hypothyroidism of TDT patients
1341PDF: 1005HTML: 340 -
Concordance Rate of Fasting Plasma Glucose (PG) and 2-hour PG post Oral Glucose Tolerance Test (OGTT) in Patients with new diagnosis of Thalassemia-Related Diabetes Mellitus (Th-RDM):Implications for Clinical Practice OGTT concordance rate in thalassemia major
802PDF: 605Html: 148 -
EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS IN THE MEDITERRANEAN AREA
2339PDF: 1040HTML: 4987 -
EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT Sinopharm Vaccination in Iranian Patients with Hemoglobinopathies
1799PDF: 778HTML: 245 -
PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?
3016PDF: 1022HTML: 2119Cover letter: 205 -
THE PERFORMANCE OF HOMA 2 COMPARED TO DYNAMIC MARKERS OF INSULIN SECRETION AND SENSITIVITY/RESISTANCE FOR PREDICTING DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β-THALASSEMIA: THE EXPERIENCE OF A SINGLE CENTRE HOMA 2 and DYNAMIC MARKERS OF INSULIN SECRETION FOR PREDICTING DYSGLYCEMIA in TDT
218PDF: 214HTML: 55







